Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01121640 · ClinicalTrials.gov registry record · NA
A Trial Using Novel Markers to Predict Malignancy in Elevated-Risk Women
A NA study, sponsored by Fred Hutchinson Cancer Center.
- Completed
- Registry status
- NA
- Development phase
- 854
- Enrollment target
NCT01121640 is a NA study that has completed, run by Fred Hutchinson Cancer Center. The registered enrollment target is 854 participants.
The verdict
NCT01121640, a NA study, has completed, sponsored by Fred Hutchinson Cancer Center.
- COMPLETED
- Registry status
- NA
- Development phase
- 854 participants
- Enrollment target
Study Summary
The Novel Markers Trial will compare the safety, feasibility and effectiveness of two different epithelial ovarian cancer screening strategies that use CA125 and add HE4 as either a first or second line screen. This study is the next step in a larger research effort to develop a blood test that can be used as a screening method for the early detection of epithelial ovarian cancer.
Interventions
- PROCEDURE Transvaginal Ultrasound
- PROCEDURE CA125 assay on Abbott Architect i1000SR platform
- PROCEDURE HE4 assay on Architect i1000SR platform
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 854 participants |
| Start Date | 2009-11 |
| Est. Completion | 2015-05-07 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01121640
The ClinicalTrials.gov registry entry for NCT01121640 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 854 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Fred Hutchinson Cancer Center, which has 483 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Transvaginal Ultrasound is the first listed.
NCT01121640 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01121640 about?
NCT01121640 is a clinical study titled "A Trial Using Novel Markers to Predict Malignancy in Elevated-Risk Women". The Novel Markers Trial will compare the safety, feasibility and effectiveness of two different epithelial ovarian cancer screening strategies that use CA125 and add HE4 as either a first or second line screen. This study is the next step in a larger research effort to develop a blood test that can ...
What is the current status of trial NCT01121640?
This trial is currently completed. It is a NA study. The enrollment target is 854 participants. The study started on 2009-11. Estimated completion is 2015-05-07.
What interventions are being tested in trial NCT01121640?
The interventions under investigation include: Transvaginal Ultrasound (PROCEDURE), CA125 assay on Abbott Architect i1000SR platform (PROCEDURE), HE4 assay on Architect i1000SR platform (PROCEDURE).
Who is sponsoring clinical trial NCT01121640?
This trial is sponsored by Fred Hutchinson Cancer Center, which has 483 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.